Effects of Ethinylestradiol and Cyproterone acetate combined with Mifepristone in treatment of perimenopausal patients with abnormal uterine bleeding
Objective:To observe effects of Ethinylestradiol and Cyproterone acetate combined with Mifepristone in treatment of patients with perimenopausal abnormal uterine bleeding (AUB). Methods:The clinical data of 118 patients with perimenopausal AUB admitted to this hospital from August 2021 to May 2023 were retrospectively analyzed. According to different treatment plans,they were divided into observation group and control group,59 cases in each group. The control group was treated with Mifepristone,while the observation group was treated with Ethinylestradiol and Cyproterone acetate tablets on the basis of that of the control group. The clinical efficacy,the levels of disease-related indexes[menstrual period,menstrual volume,endometrial thickness,hemoglobin (Hb)]levels,the serum sex hormone[progesterone,follicle stimulating hormone (FSH),estradiol (E2),luteinizing hormone (LH)],the serum angiopoietin-1 (Ang-1) and the angiopoietin-2 (Ang-2) before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of the observation group was 96.61％ (57/59),which was higher than 84.75％ (50/59) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the menstrual period levels of the two groups were shorter than those before the treatment,and that in the observation group was shorter than that in the control group;the menstrual volume levels of the two groups were less than those before the treatment,and that in the observation group was less than that in the control group;the endometrial thickness levels of the two groups were smaller than those before the treatment,and that in the observation group was smaller than that in the control group;the Hb levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant (P<0.05). After 3 months of treatment,the levels of LH,FSH,E2 and progesterone in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). After 3 months of treatment,the levels of Ang-1 and Ang-2 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Ethinylestradiol and Cyproterone acetate combined with Mifepristone in the treatment of the perimenopausal AUB patients can improve the total effective rate of treatment,improve the levels of disease-related indexes,and reduce the levels of serum sex hormone indexes as well as the Ang-1 and Ang-2 levels. Moreover,it is superior to simple Mifepristone treatment.
Ethinylestradiol and Cyproterone acetateMifepristonePerimenopausal periodAbnormal uterine bleedingSex hormoneSerum angiopoietin-1
万方数据
维普
